Blood Test to Detect Clinically Significant Prostate Cancer
Studies a blood test looking at exosome RNA to diagnose serious prostate cancer in adults.
Plain-language title generated from the registry record
Registry title: Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer
Key facts
- Where
- Lanzhou, Weinan, Xi'an, Xianyang, Xining, Yan’an, and Yinchuan, ChinaSee the 9 sites
Where in China
- The First Hospital of Lanzhou UniversityLanzhou, ChinaTaking people
- Weinan Central HospitalWeinan, ChinaTaking people
- Shaanxi provincial people's hospitalXi'an, ChinaTaking people
- Xijing 986 HospitalXi'an, ChinaTaking people
- Xijing hospitalXi'an, ChinaTaking people
- The Second Affiliated Hospital of Shaanxi University of Chinese MedicineXianyang, ChinaTaking people
- Qinghai university affiliated hospitalXining, ChinaTaking people
- Yan'an University Affiliated HospitalYan’an, ChinaTaking people
- General Hospital of Ningxia Medical UniversityYinchuan, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Xijing Hospital
- Trial code
- NCT07492927
- Record updated
- 25 March 2026
- Original description
The aim of the present study is to investigate a plasma exosome RNA signature to diagnose clinically significant prostate cancer.Read full original descriptionShow less
Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer
The aim of the present study is to investigate a plasma exosome RNA signature to diagnose clinically significant prostate cancer.
Inclusion: Blood prostate-specific antigen PSA>4ng/dl; Patients suspected of having prostate cancer through clinical symptoms, digital rectal examination, ultrasound examination, magnetic resonance imaging; The patient is willing to undergo prostate biopsy.
Exclusion: Previous diagnosis of prostate cancer through prostate biopsy; History of other malignant tumors in the past two years; According to the research physician''s judgment, serious complications may occur and affect the normal conduct of the experiment.